Supplementary Information

Succinct synthesis of saturated hydroxy fatty acids and *in vitro* evaluation of all hydroxylauric acids at FFA1, FFA4 and GPR84

Mads Holmgaard Kaspersen, Laura Jenkins, Julia Dunlop, Graeme Milligan, Trond Ulven*

*Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark

b Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

*Email: ulven@sdu.dk

Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synthetic procedures</td>
<td>2</td>
</tr>
<tr>
<td>Concentration-response curves</td>
<td>4</td>
</tr>
<tr>
<td>References</td>
<td>5</td>
</tr>
<tr>
<td>NMR spectra</td>
<td>6</td>
</tr>
</tbody>
</table>
Synthetic procedures

2-Hydroxylauric acid (2-HLA). Lauric acid (200 mg, 1.0 mmol) was dissolved in SOCl₂ (0.36 mL) and the reaction was heated to 50 °C for 15 min. Bromine (0.25 mL, 5.0 mmol) was added and the reaction was stirred at 50 °C for 22 h. The reaction mixture was cooled to 0°C and concentrated, aqueous Na₂SO₃ was added until the disappearance of the colour, and the solution was acidified to pH 1 with 2M HCl. The aqueous phase was extracted with dichloromethane (3×10 mL). The combined organic phases were dried over Na₂SO₄ and evaporated in vacuo. The crude product was dissolved in 2M NaOH (4.75 mL) and heated to 85 °C for 17 h. The reaction mixture was cooled to 0 °C and acidified with concentrated HCl to pH 1. The reaction mixture was extracted with ethyl acetate (3×30 mL). The combined organic phases were dried over Na₂SO₄ and evaporated in vacuo. The crude was purified by column chromatography (1:1:100 MeOH:AcOH:DCM) yielding 110 mg (53%) of the product as a white solid: ¹H NMR (400 MHz, CD₃OD) δ 4.02 (dd, J = 7.7, 4.4 Hz, 1H), 1.73 – 1.62 (m, 1H), 1.61 – 1.50 (m, 1H), 1.39 – 1.31 (m, 2H), 1.24 (d, J = 18.5 Hz, 14H), 0.82 (t, J = 6.9 Hz, 3H); ¹³C NMR (101 MHz, CD₃OD) δ 178.1, 71.5, 35.4, 33.1, 30.7, 30.7, 30.6, 30.5, 30.5, 26.1, 23.7, 14.4; ESI-HRMS: (M+Na⁺) calcd for C₁₂H₂₄NaO₃: 239.1618, found: 239.1617

Ethyl 3-oxolaurate. NaH (40 mg, 60 % w/w, 1.0 mmol) was suspended in dry THF (4.5 mL). The suspension was cooled to 0 °C and ethyl acetoacetate (110 µL, 0.87 mmol) was added. When bubbling had seized, n-butyl lithium (2.5 M in hexanes, 0.37 mL, 0.93 mmol) was added. After half an hour 1-bromo-octane was added (135 µL, 0.78 mmol), the reaction was then allowed to reach room temperature and stirred for 16 h. The reaction mixture was concentrated, NH₄Cl (sat. aq., 3 mL) was added, the pH was adjusted to 7 with aqueous HCl (1 M), and the aqueous phase was extracted with ethyl acetate (3×15 mL). The combined organic phase was dried over Na₂SO₄ and evaporated in vacuo. The crude was purified by column chromatography (1:20 ethyl acetate:petroleum ether) yielding 180 mg (96%) of the product as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 4.20 (q, J = 7.1 Hz, 2H), 3.43 (s, 2H), 2.53 (t, J = 7.4 Hz, 2H), 1.64 – 1.53 (m, 2H), 1.34 – 1.24 (m, 15H), 0.88 (t, J = 6.9 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 203.0, 167.3, 61.3, 49.3, 43.1,
was blown away under a stream of nitrogen yielding the desired compound.

31.9, 29.4, 29.3, 29.2, 29.0, 23.5, 22.6, 14.1, 14.1. NMR is consistent with previously reported data. Approximately 15 % of the corresponding enol was observed in the spectra.

3-Hydroxylauric acid (3-HLA). Ethyl 3-oxolaurate (147 mg, 0.61 mmol) was dissolved in THF (1 mL) and absolute ethanol (0.5 mL). The solution was cooled to 0 °C, NaBH₄ (29 mg, 0.79 mmol) was added and the reaction was stirred for 2 h before addition of aqueous HCl (0.5 M, 6 mL) and brine (9 mL). The aqueous phase was extracted with ethyl acetate (3×15 mL). The combined organic phase was dried over Na₂SO₄ and evaporated in vacuo. The crude was dissolved in THF (1.5 mL) and added LiOH•H₂O (55 mg, 1.31 mmol) dissolved in H₂O (0.75 mL). The reaction was stirred 21 h and then acidified to pH 1 with HCl (2 M). Brine (9 mL) was added and the aqueous phase was extracted with ethyl acetate (3×15 mL). The combined organic phase was dried over Na₂SO₄ and concentrated in vacuo. The crude was purified by column chromatography (1:1:100 AcOH:MeOH:DCM) yielding the desired product as a white solid (44 mg, 36% over two steps): ¹H NMR (400 MHz, CD₃OD) δ 4.02 – 3.93 (m, 1H), 3.73 – 3.66 (m, 1H), 2.40 (qd, J = 15.2, 6.5 Hz, 2H), 1.48 (d, J = 6.3 Hz, 2H), 1.30 (d, J = 1.8 Hz, 14H), 0.90 (t, J = 6.9 Hz, 3H); ¹³C NMR (101 MHz, CD₃OD) δ 175.7, 69.4, 49.7, 49.5, 49.2, 49.0, 48.8, 48.6, 48.4, 43.3, 38.1, 33.1, 30.7, 30.7, 30.5, 26.7, 23.7, 14.4; ESI-HRMS: calcd for C₁₂H₂₄NaO₃ (M+Na⁺) 239.1618, found 239.1610.

Sodium 4-hydroxylaurate (4-HLA). 4-Dodecanolide (105 µL, 0.50 mmol) and NaOH (21 mg, 0.53 mmol) was dissolved in methanol (1 mL) and stirred for 24 h at room temperature. The solvent was blown away under a stream of nitrogen yielding the desired compound as a white, waxy solid (112 mg, 93 %): ¹H NMR (400 MHz, CD₃OD) δ 3.58 – 3.50 (m, 1H), 3.35 (s, 1H), 2.35 – 2.21 (m, 2H), 1.81 – 1.72 (m, 1H), 1.70 – 1.60 (m, 1H), 1.46 – 1.28 (m, 14H), 0.90 (t, J = 6.9 Hz, 3H); ¹³C NMR (101 MHz, CD₃OD) δ 183.0, 72.9, 38.5, 35.8, 34.9, 33.1, 30.9, 30.8, 30.4, 26.9, 23.7, 14.4; ESI-HRMS: calcd for C₁₂H₂₄NaO₃ (M+Na⁺) 239.1618, found 239.1618.

Sodium 5-hydroxylaurate (5-HLA). 5-Dodecanolide (105 µL, 0.50 mmol) and NaOH (21 mg, 0.50 mmol) was dissolved in methanol (1 mL). It was stirred for 24 h at room temperature. The solvent was blown away under a stream of nitrogen yielding the desired compound as a white solid (105 mg, 88%): ¹H NMR (400 MHz, CD₃OD) δ 3.57 – 3.49 (m, 1H), 2.17 (t, J = 7.5 Hz, 2H), 1.79 – 1.57 (m,
2H), 1.52 – 1.27 (m, 14H), 0.90 (t, J = 6.9 Hz, 3H); $^{13}$C NMR (101 MHz, CD$_3$OD) δ 182.9, 72.2, 39.1, 38.5, 38.4, 33.0, 30.9, 30.5, 26.9, 23.8, 23.7, 14.4; ESI-HRMS: (M+Na$^+$) calcd for C$_{12}$H$_{24}$NaO$_3$ 239.1618, found 239.1623.

**Concentration-response curves**

![Graph](image1)

**Figure S1.** Concentration-response curves for lauric acid (C12), 2-HLA, 6-HLA and TUG-770 on FFA1.$^5$\textsuperscript{6}

![Graph](image2)

**Figure S2.** Concentration-response curves for 2-HLA, 3-HLA, 4-HLA and 12-HLA on GPR84.$^7$
References

NMR spectra

2-Hydroxydodecanoic acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
Ethyl 3-oxolaurate

$^1$H NMR (400 MHz, CDCl$_3$), $^{13}$C NMR (101 MHz, CDCl$_3$)
3-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
Sodium 4-hydroxylaurate

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
Sodium 5-hydroxylaurate

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
6-Hydroxy-4-dodecynoic acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
6-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
7-Hydroxy-5-dodecynoic acid

\(^1\text{H NMR (400 MHz, CDCl}_3\), \(^{13}\text{C NMR (101 MHz, CDCl}_3\))
7-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
8-Hydroxy-6-dodecynoic acid

$^1$H NMR (400 MHz, CDCl$_3$), $^{13}$C NMR (101 MHz, CDCl$_3$)
8-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)

[Image of NMR spectra]

[Structural diagram of 8-Hydroxylauric acid]
9-Hydroxy-7-dodecynoic acid

$^1$H NMR (400 MHz, CDCl$_3$), $^{13}$C NMR (101 MHz, CDCl$_3$)
9-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
10-Hydroxy-8-dodecynoic acid

\(^1\text{H NMR (400 MHz, CD}_2\text{OD)}, ^{13}\text{C NMR (101 MHz, CD}_2\text{OD)}\)

![NMR spectra](image)
10-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)
11-Hydroxy-9-dodecynoic acid

$^1$H NMR (400 MHz, CDCl$_3$), $^{13}$C NMR (101 MHz, CDCl$_3$)
11-Hydroxylauric acid

$^1$H NMR (400 MHz, CD$_3$OD), $^{13}$C NMR (101 MHz, CD$_3$OD)